Therapeutic Experience with Oral Finasteride for Androgenetic Alopecia in Female-to-Male Transgender Patients

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This review discusses the effects of testosterone therapy for transgender men, noting desired outcomes and potential risks, but reports no new research findings; the authors highlight a lack of high-quality data due to various study limitations.

This review discusses various classification systems for patterned hair loss in both sexes and reports no new clinical findings, highlighting the Hamilton-Norwood and Ludwig systems as the most commonly used.

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

This study found that testosterone therapy in trans men increased facial and body hair growth while the prevalence and severity of acne peaked at 6 months but were primarily mild after long-term treatment.

This article reviews the use of trichoscopy for diagnosing various types of alopecia and reports no new clinical results; it is suggested as a non-invasive method for diagnosis and monitoring treatment responses.

This article examines the evidence regarding finasteride's sexual side effects and offers recommendations for patient counseling but reports no new clinical findings.

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

Hair loss linked to higher heart disease risk in both men and women.

This review discusses the limited objective evidence for using finasteride in women with alopecia, suggesting that it could be considered for those who don't benefit from minoxidil, but reports no new clinical results.

This study found a significant association between androgenetic alopecia and metabolic syndrome, highlighting high-density lipoprotein cholesterol as a particularly important factor.

The guideline recommends mental health involvement in diagnosing gender identity disorder and outlines hormone and surgical treatment protocols, emphasizing safety, informed consent, and long-term monitoring.

This review discusses hirsutism management guidelines, recommending androgen testing only for women with abnormal hirsutism scores and advocating for combined therapy approaches depending on severity and underlying conditions, but it reports no new clinical results.

This study found no support for the idea that male-pattern baldness in female-to-male transsexuals indicates an increased risk of coronary heart disease through androgenic effects on classic risk factors.

This review discusses the genetic factors contributing to androgenetic alopecia and highlights the potential for developing more effective therapies based on recent discoveries, but reports no new clinical results.

In this study, cross-sex hormone therapy affected hair growth patterns differently, with estrogen reducing hair growth in male-to-female transsexuals and testosterone increasing it in female-to-male transsexuals; however, male typical hair diameters were not fully reached in the latter group after 12 months.

This article discusses the treatment of androgenetic alopecia and alopecia areata with finasteride and minoxidil but reports no new clinical results.

Finasteride treats enlarged prostate and may help with baldness, but effects on sexual function and male fetuses are unclear.